Vascular Function and Intima-media Thickness of a Leg Artery in Peripheral Artery Disease: A Comparison of Buerger Disease and Atherosclerotic Peripheral Artery Disease

Akimichi Iwamoto¹, Masato Kajikawa² ³, Tatsuya Maruhashi¹, Yumiko Iwamoto¹, Nozomu Oda¹, Shinji Kishimoto¹, Shogo Matsui¹, Yasuki Kihara¹, Kazuaki Chayama⁴, Chikara Goto⁵, Kensuke Noma³ ⁶, Yoshiki Aibara³, Ayumu Nakashima³ and Yukihito Higashi³ ⁶

¹ Department of Cardiovascular Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
² Global Career Design Center, Hiroshima University, Hiroshima, Japan
³ Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
⁴ Department of Gastroenterology and Metabolism, Institute of Biomedical and Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima, Japan
⁵ Hiroshima International University, Hiroshima, Japan
⁶ Division of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan

Aim: Both vascular function and structure are independent predictors of cardiovascular events. The purpose of this study was to evaluate vascular function and structure of a leg artery in patients with peripheral artery disease (PAD).

Methods: We measured flow-mediated vasodilatation (FMD) and nitroglycerine-induced vasodilation (NID) as indices of vascular function and intima-media thickness (IMT) as an index of vascular structure of the popliteal artery in 100 subjects, including 20 patients with Buerger disease and 30 patients with atherosclerotic PAD, 20 age- and sex-matched subjects without Buerger disease (control group) and 30 age- and sex-matched patients without atherosclerotic PAD (control group).

Results: IMT was significantly larger in the Buerger group than in the control group (Buerger, 0.63 ± 0.20 mm; control, 0.50 ± 0.07 mm; P < 0.01), whereas there were no significant differences in FMD and NID between the two groups. IMT was significantly larger in the atherosclerotic PAD group than in the control group (atherosclerotic PAD, 0.80 ± 0.22 mm; control, 0.65 ± 0.14 mm; P < 0.01), and FMD and NID were significantly smaller in the atherosclerotic PAD group than in the control group (FMD: atherosclerotic PAD, 3.9% ± 1.1%; control, 5.0% ± 1.8%; P < 0.01; and NID: atherosclerotic PAD, 6.1% ± 2.0%; control, 8.4% ± 2.1%; P < 0.01).

Conclusion: These findings suggest that vascular function is preserved in patients with Buerger disease and that both vascular function and vascular structure are impaired in patients with atherosclerotic PAD.

See editorial vol. 23: 1255-1256

Key words: Peripheral artery disease, Buerger disease, Flow-mediated vasodilatation, Nitroglycerine-induced vasodilation, Intima-media thickness

Copyright © 2016 Japan Atherosclerosis Society
This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
any cause of death are significantly higher in patients with atherosclerotic PAD than in patients with Buerger disease, and the mortality rate in patients with Buerger disease is not higher than that in age-matched control subjects.

Intima-media thickness (IMT) is an established index of structural change of an artery. IMT, particularly that of the carotid, is associated with the presence of cardiovascular risk factors and is an independent predictor of cardiovascular events. Recently, we have shown that IMT of the brachial artery also serves as a surrogate marker for progression of atherosclerosis. However, there is little information on endothelial function and IMT of a leg artery in patients with PAD, including Buerger disease.

Endothelial function is initially impaired with progression of atherosclerosis, leading to cardiovascular events. Evaluation of flow-mediated vasodilation (FMD) and nitroglycerine-induced vasodilation (NID) is useful for assessing vascular function. Previous studies have shown that endothelial function assessed by FMD can serve as an independent predictor of cardiovascular events. Several studies have demonstrated that not only FMD but also NID is impaired in subjects with cardiovascular risk factors, patients with coronary vascular disease, and patients with PAD. Recently, we demonstrated that NID decreased in relation to cumulative cardiovascular risk factors and was therefore significantly correlated with cardiovascular risk factors as well as FMD and that impaired NID was an independent variable for critical limb ischemia. Vascular function assessed by NID per se also should predict cardiovascular outcomes.

Although some studies have shown interrelations between endothelial function assessed by FMD and that assessed by IMT in a general population, FMD and IMT were examined at different vascular sites, such as the brachial artery and common carotid artery in those studies. There is no information on differences in IMT, FMD and NID of the peripheral artery between Buerger disease and atherosclerotic PAD. Therefore, in the present study, we evaluated FMD, NID, and IMT in the same leg artery in patients with Buerger disease and patients with atherosclerotic PAD.

Methods

Subjects
A total of 100 subjects (mean age, 58.9 ± 14.1 years), including 20 patients with Buerger disease (18 men and two women, mean age: 48.9 ± 14.4 years), and 30 patients with atherosclerotic PAD (22 men and eight women, mean age: 69.5 ± 7.8 years), 20 age- and sex-matched subjects without Buerger disease (Buerger control group: 19 men and one woman, mean age: 43.0 ± 5.1 years), and 30 age- and sex-matched patients without atherosclerotic PAD (atherosclerotic PAD control group: 20 men and 10 women, mean age: 65.7 ± 7.5 years), were enrolled. Buerger disease was diagnosed by the previously reported criteria, including results of physical examinations, clinical symptoms, angiographic findings, and results of arterial duplex scanning. To rule out other vasculitis and hypercoagulable states, rheumatoid factor, lupus anticoagulants, and serologic investigations were evaluated. Atherosclerotic PAD and Buerger disease were defined as current intermittent claudication with ankle-brachial index (ABI) < 0.9, or chronic ischemic rest pain, ischemic ulcers, or gangrene attributed to objectively proven arterial occlusive disease, or history of previous intervention including angioplasty, bypass graft, and limb amputation. Diagnosis of limb ischemia was confirmed by angiography. Control subjects were matched sex and age, and had no PAD. Hypertension was defined as treatment with oral anti-hypertensive agents or systolic blood pressure of more than 140 mmHg, or diastolic blood pressure of more than 90 mmHg, in a sitting position on at least three different occasions without medication. Diabetes was defined according to the American Diabetes Association recommendation. Dyslipidemia was defined according to the third report of the National Cholesterol Education Program. We defined smokers as those who had ever smoked. Coronary heart disease included angina pectoris, myocardial infarction, and unstable angina. The vascular tests were performed without withholding medications. The ethical committees of our institutions approved the study protocol. Written informed consent for participation in the study was obtained from all subjects.

Study Protocol
We measured vascular responses to reactive hyperemia and sublingually administrated nitroglycerine in the popliteal artery without stenosis and in occluded arteries in subjects. Subjects fasted the previous night for at least 12 h. The study began at 8:30 AM. The subjects were kept in the prone position in a quiet, dark, air-conditioned room (constant temperature of 22 °C).
22°C–25°C) throughout the study. A 23-gauge polyethylene catheter was inserted into the left deep antecubital vein to obtain blood samples. Thirty minutes after maintaining the prone position, basal popliteal artery diameter and IMT were measured. Then, FMD was measured in the popliteal artery. After completion, we next measured NID with confirmation that the popliteal artery diameter had recovered to the baseline value. The observers were blind to the protocol of this study.

Measurement of Popliteal Artery IMT
The ultrasound unit Aloka-a7 (Aloka Co, Tokyo, Japan) equipped with a linear, phased-array high-frequency (13-MHz) transducer was used for scanning the popliteal artery. Ultrasound longitudinal images of the popliteal artery were acquired at the end of the diastole (defined as the R wave of an electrocardiogram), in which the far wall intima-media interface was clearly defined. The leading edge of the intima and the media-adventitia interface were traced as continuous lines. A total of 20 points over a 3-mm length of IMT in the 10-mm longitudinal image depicted in the analysis display were measured and the mean value per image was automatically calculated. IMT was measured at the same point in each different image. The average of mean values obtained from 10 cardiac cycles was defined as IMT of the popliteal artery. All of the duplex ultrasonography scans were performed by ultrasonographic specialists.

The coefficient of variation for IMT was 4.9% in our laboratory.

Measurement of Vascular Function
A high-resolution linear artery transducer was coupled to computer-assisted analysis software (Aloka-a7, ALOKA Co., Tokyo, Japan) that used an automated edge detection system for measurement of artery diameter. A blood pressure cuff was placed around the thigh. The target artery was scanned longitudinally. When the clearest B-mode image of the intimal interfaces between the lumen and vessel wall was obtained, the transducer was held at the same point throughout the scan by a special probe holder (MP-PH0001, ALOKA Co.) to ensure consistency of the image. A baseline image was acquired and blood flow was estimated by time averaging the pulsed Doppler velocity signal obtained from a sample volume. Then the blood pressure cuff was inflated to 50 mm Hg above systolic pressure for 5 min. Depth and gain setting were set to optimize the images of the arterial lumen wall interface. When the tracking gate was placed on the intima, the artery diameter was automatically tracked and the waveform of diameter changes over the cardiac cycle was displayed in real time using the FMD mode of the tracking system. This allowed the ultrasound images to be optimized at the start of the scan and the transducer position to be adjusted immediately for optimal tracking performance throughout the scan. Pulsed Doppler flow was assessed at baseline and during peak hyperemic flow, which was confirmed to occur within 15 s after cuff deflation. Blood flow velocity was calculated from the color Doppler data and was displayed as a waveform in real time. The baseline longitudinal image of the artery was acquired for 30 s and then the blood pressure cuff was inflated to 50 mm Hg above systolic pressure for 5 min. The longitudinal image of the artery was recorded continuously until 5 min after cuff deflation. Pulsed Doppler velocity signals were obtained for 20 s at baseline and for 10 s immediately after cuff deflation. Changes in brachial artery diameter were immediately expressed as per cent change relative to the vessel diameter before cuff inflation. FMD was calculated as the per cent change in peak vessel diameter from the baseline value. %FMD [(peak diameter − baseline diameter)/baseline diameter] was used for analysis. Blood flow volume was calculated by multiplying the Doppler flow velocity (corrected for the angle) by heart rate and vessel cross-sectional area (r²). Reactive hyperemia was calculated as the maximum percentage increase in flow after cuff deflation compared with baseline flow. After a 10-min period to allow baseline conditions of the artery to be reestablished, another baseline scan was performed.

The response to nitroglycerine was used for assessment of endothelium-independent vasodilation. NID was measured as described previously 28. Briefly, after acquiring baseline rest images for 30 s, a sublingual tablet (75 µg nitroglycerine) was given, and images of the artery were recorded continuously until the dilation reached a plateau after administration of nitroglycerine. Subjects who had received nitrate treatment and subjects in whom the sublingually administered nitroglycerine tablet did not dissolve during the measurement, were excluded from this study. NID was automatically calculated as a per cent change in peak vessel diameter from the baseline value. Percentage of NID [(peak diameter − baseline diameter)/baseline diameter] was used for analysis.

The coefficient of variation for the baseline diameter was 2.9% in our laboratory.

Analytical Methods
Samples of venous blood were placed in tubes containing sodium ethylenediamine tetracetic acid (1 mg/mL) and in polystyrene tubes. The ethylenediamine tetracetic acid-containing tubes were chilled
Table 1. Clinical Characteristics of The Subjects

| Variable                          | Total (n = 100) | Buerger disease No (n = 20) | Buerger disease Yes (n = 20) | P value | Atherosclerotic PAD No (n = 30) | Atherosclerotic PAD Yes (n = 30) | P value |
|----------------------------------|----------------|-----------------------------|-----------------------------|---------|---------------------------------|----------------------------------|---------|
| Age, yr                          | 58.9 ± 14.1    | 43.0 ± 5.1                  | 48.9 ± 14.4                 | 0.09    | 65.7 ± 7.5                     | 69.5 ± 7.8                        | 0.06    |
| Sex, men/women                   | 79/21          | 19/1                        | 18/2                        | 0.54    | 20/10                           | 22/8                             | 0.57    |
| Body mass index, kg/m²           | 22.7 ± 3.2     | 22.7 ± 3.0                  | 22.4 ± 3.1                  | 0.75    | 23.7 ± 3.1                     | 21.9 ± 3.2                        | 0.03    |
| Systolic blood pressure, mmHg    | 126.8 ± 19.8   | 118.1 ± 8.7                 | 117.2 ± 16.7                | 0.84    | 130.9 ± 17.8                   | 134.8 ± 24.1                      | 0.49    |
| Diastolic blood pressure, mmHg   | 74.5 ± 11.9    | 74.7 ± 7.4                  | 70.2 ± 13.2                 | 0.20    | 77.6 ± 11.5                    | 74.3 ± 13.3                       | 0.31    |
| Heart rate, bpm                  | 72.5 ± 12.1    | 71.3 ± 9.9                  | 68.8 ± 11.9                 | 0.48    | 69.3 ± 10.5                    | 79.0 ± 13.0                       | <0.01   |
| Total cholesterol, mg/dL         | 172.8 ± 31.4   | 178.4 ± 18.8                | 171.3 ± 34.8                | 0.57    | 175.0 ± 20.1                   | 170.3 ± 39.3                      | 0.61    |
| Triglycerides, mg/dL             | 116.1 ± 58.5   | 81.4 ± 26.9                 | 125.9 ± 67.1                | 0.07    | 127.7 ± 67.3                   | 110.2 ± 47.7                      | 0.28    |
| High-density lipoprotein cholesterol, mg/dL | 56.0 ± 17.2  | 63.1 ± 20.5                 | 49.0 ± 11.3                 | 0.03    | 57.9 ± 12.7                    | 56.8 ± 21.8                       | 0.83    |
| Low-density lipoprotein cholesterol, mg/dL | 98.0 ± 25.5 | 100.0 ± 20.4                | 102.4 ± 29.0                | 0.83    | 100.1 ± 19.6                   | 92.2 ± 29.3                       | 0.27    |
| Glucose, mg/dL                   | 116.4 ± 35.6   | 97.9 ± 16.6                 | 101.1 ± 20.4                | 0.69    | 114.6 ± 21.8                   | 133.9 ± 48.6                      | 0.07    |
| Ankle-brachial index             | 1.00 ± 0.24    | 1.20 ± 0.05                 | 0.82 ± 0.25                 | <0.01   | 1.15 ± 0.07                    | 0.83 ± 0.21                       | <0.01   |

Rutherford class

|          | 0, n (%) | 1, n (%) | 2, n (%) | 3, n (%) | 4, n (%) | 5, n (%) | 6, n (%) |
|----------|----------|----------|----------|----------|----------|----------|----------|
| Stage    |          |          |          |          |          |          |          |
| I        | 55 (55.0)| 20 (100.0)| 4 (20.0)| <0.01   | 30 (100.0)| 1 (3.3)  | <0.01    |
| II       | 5 (5.0)  | 0 (0.0)  | 4 (20.0)| 0.01    | 0 (0.0)  | 1 (3.3)  | 0.24     |
| III      | 6 (6.0)  | 0 (0.0)  | 2 (10.0)| 0.09    | 0 (0.0)  | 4 (13.3) | 0.02     |
| IV       | 7 (7.0)  | 0 (0.0)  | 1 (5.0) | 0.23    | 0 (0.0)  | 6 (20.0) | <0.01    |
| Stage    |          |          |          |          |          |          |          |
| I        | 55 (55.0)| 20 (100.0)| 4 (20.0)| <0.01   | 3 (100.0)| 1 (3.3)  | <0.01    |
| II       | 18 (18.0)| 0 (0.0)  | 7 (35.0)| <0.01   | 0 (0.0)  | 11 (36.6)| <0.01    |
| III      | 5 (5.0)  | 0 (0.0)  | 1 (5.0) | 0.23    | 0 (0.0)  | 4 (13.3) | 0.02     |
| IV       | 22 (22.0)| 0 (0.0)  | 8 (40.0)| <0.01   | 0 (0.0)  | 14 (46.7)| <0.01    |

Fontaine class

|          | 0, n (%) | 1, n (%) | 2, n (%) | 3, n (%) | 4, n (%) | 5, n (%) | 6, n (%) |
|----------|----------|----------|----------|----------|----------|----------|----------|
| Stage    |          |          |          |          |          |          |          |
| I        | 57 (57.0)| 1 (5.0)  | 3 (15.0)| 0.28    | 25 (83.3)| 28 (93.3)| 0.22     |
| II       | 32 (32.0)| 2 (10.0)| 4 (20.0)| 0.37    | 15 (50.0)| 11 (36.7)| 0.30     |
| III      | 38 (38.0)| 0 (0.0)  | 1 (5.0) | 0.23    | 17 (56.7)| 20 (66.7)| 0.43     |
| IV       | 22 (22.0)| 0 (0.0)  | 0 (0.0) | ND      | 7 (23.3)| 15 (50.0)| 0.03     |

Medical history, n (%)

- Hypertension: 57 (57.0)
- Dyslipidemia: 32 (32.0)
- Diabetes mellitus: 38 (38.0)
- Previous coronary heart disease: 22 (22.0)
- Smoker (current): 20 (20.0)
- Smoker (past): 49 (49.0)
- Medications, n (%)
  - Calcium-channel blockers: 24 (24.0)
  - Renin angiotensin system inhibitors: 34 (34.0)
  - Statins: 28 (28.0)
  - Medically treated diabetes: 29 (29.0)

PAD indicates peripheral arterial disease; ND, not detected.
All results are presented as means ± SD.

promptly in an ice bath. Plasma was immediately separated by centrifugation at 3100 g for 10 min at 4°C, and serum was separated by centrifugation at 1000 g for 10 min at room temperature. Samples were stored at −80°C until the time of assay. Serum concentrations of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glucose, and electrolytes were determined by routine chemical methods.

Statistical Analysis
Results are presented as the means ± standard deviation (SD) for continuous variables and as percentages for categorical variables. Statistical significance was set at a level of P < 0.05. Comparisons between groups were carried out using P for trend
There were no significant differences in other parameters between the two groups.

Results

Baseline Clinical Characteristics

The baseline clinical characteristics are summarized in Table 1. Of the 20 patients with Buerger disease, 18 (90.0%) were men and two (10.0%) were women; three (15.0%) had hypertension, four (20.0%) had dyslipidemia, one (5.0%) had diabetes mellitus, four (20.0%) were current smokers and none had previous coronary heart disease. Serum concentration of high-density lipoprotein cholesterol and ABI were significantly lower in the Buerger group than in the control group. There were no significant differences in other parameters between the two groups.

Of the 30 subjects with atherosclerotic PAD, 22 (73.3%) were men and eight (26.7%) were women; 28 (93.3%) had hypertension, 11 (36.7%) had dyslipidemia, 20 (66.7%) had diabetes mellitus, four (13.3%) were current smokers, and 15 (50.0%) had previous coronary heart disease. Heart rate, serum concentration of glucose, and ratio of previous coronary heart disease were significantly higher in the atherosclerotic PAD group than in the atherosclerotic PAD control group. Body mass index and ABI were significantly lower in the atherosclerotic PAD group than in the atherosclerotic PAD control group. There were no significant differences in other parameters between the two groups.
Vascular Function and Structure in Patients with Buerger Disease and Patients with Atherosclerotic PAD

There were no significant differences in FMD and NID between the Buerger group and control group (FMD: Buerger group, 5.7% ± 1.8%; control group, 6.1% ± 0.9%; P = 0.40; and NID: Buerger group, 8.6% ± 3.6%; control group, 9.8% ± 1.7%; P = 0.19, Fig. 1). IMT was significantly larger in the Buerger group than in the control group (Buerger group, 0.63 ± 0.20 mm; control group, 0.50 ± 0.07 mm; P = 0.01, Fig. 2).

FMD and NID were significantly smaller in the atherosclerotic PAD group than in the control group (FMD: atherosclerotic PAD group, 3.9% ± 1.1%; control group, 5.0% ± 1.8%; P < 0.01 and NID: atherosclerotic PAD group, 6.1% ± 2.0%; control group, 8.4% ± 2.1%; P < 0.01, Fig. 3). IMT was significantly larger in the atherosclerotic PAD group than in the control group (atherosclerotic PAD group, 0.80 ± 0.22 mm; control group, 0.65 ± 0.14 mm; P < 0.01, Fig. 4).

Discussion

In the present study, we demonstrated that IMT of the popliteal artery was increased both in patients with Buerger disease and patients with atherosclerotic PAD compared with those in control groups. FMD and NID of the popliteal artery were impaired in patients with atherosclerotic PAD but not in patients with Buerger disease. These findings suggest that vascular function of a leg artery is preserved in patients with Buerger disease and that both vascular function and vascular structure of a leg artery are impaired in patients with atherosclerotic PAD.

It is well known that patients with PAD, particularly atherosclerotic PAD, have a high prevalence of cardiovascular morbidity and mortality. Atherosclerosis progressively develops with aging in patients with atherosclerotic PAD. Endothelial dysfunction is the initial step in the pathogenesis of atherosclerosis, resulting in cardiovascular complications. Recently, we reported that both FMD and NID were impaired in patients with atherosclerotic PAD. In addition, brachial IMT was correlated with NID, suggesting that vascular smooth muscle function is also impaired in relation to increased brachial IMT. In the present study, in the popliteal artery also, IMT was increased and FMD and NID were impaired in patients with atherosclerotic PAD, suggesting that atherosclerotic PAD has an advanced vascular failure. Severe vascular failure may contribute to the high cardiovascular morbidity and mortality rates in atherosclerotic PAD.

On the other hand, it has been reported that there is no significant difference in the rate of mortality between patients with Buerger disease and normal populations. Some investigators have reported that the survival rate of patients with Buerger disease is significantly lower than that in the general population. Cumulative survival rate was significantly higher in
patients with Buerger disease than in patients with atherosclerotic PAD\(^1,5,37\). In the present study, vascular function, including endothelial function and vascular smooth muscle function, were not impaired in patients with Buerger disease. In addition, in a previous study, we have shown that confounding factors for endothelial function, such as oxidative stress markers, number of endothelial progenitor cells, and cell migration response to vascular endothelial growth factor, other than an inflammation marker, are similar in patients with Buerger disease and healthy controls\(^38\). Interestingly, IMT in the popliteal artery was larger in the Buerger group than in the control group, while IMT in the popliteal artery was smaller in the Buerger group than in the atherosclerotic PAD group. There has been no information on IMT in leg arteries of patients with Buerger disease. The precise reason for the increase in IMT in the popliteal artery in Buerger disease remains unclear.

In conclusion, patients with Buerger disease had normal vascular function but large IMT compared with that in age- and sex-matched controls, and patients with atherosclerotic PAD had abnormal vascular function and large IMT compared with that in age- and sex-matched controls. Our results may partially explain why there are differences in the rates of morbidity and mortality of cardiovascular diseases between patients with Buerger disease and patients with atherosclerotic PAD. Further studies are needed to evaluate vascular function and structure, and outcomes during a long-term follow-up period in patients with Buerger disease and patients with atherosclerotic PAD.

**Acknowledgments**

We thank Megumi Wakisaka, Ki-ichiro Kawano and Satoko Michiyama for their excellent secretarial assistance.

**Sources of Founding**

This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (1859081500 and 21590898) and a Grant in Aid of Japanese Atherosclerosis Prevention Fund.

**Disclosures**

None.

**References**

1) Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauer MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386
2) Steg PG, Bhatt DL, Wilson PW, D’Agostino Sr R, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-1206
3) Kojima I, Ninomiya T, Hata J, Fukuhara M, Hirakawa Y, Mukai N, Yoshida D, Kitazono T, Kiyohara Y. A low ankle brachial index is associated with an increased risk of cardiovascular disease: the Hisayama study. J Atheroscler Thromb. 2014; 21: 966-973
4) Ohta T, Shionoya S. Fate of the ischaemic limb in Buerger’s disease. Br J Surg. 1988; 75: 259-262
5) Mills JL, Porter JM. Buerger’s disease: a review and update. Semin Vasc Surg. 1993; 6: 14-23
6) O’Leary DH, Polak JF, Kronmal RA, Savage PJ, Borhani NO, Kittner SJ, Tracy R, Gardin JM, Price TR, Furberg CD. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke 1996; 27: 224-231
7) Lind L. Flow-mediated vasodilation was found to be an independent predictor of changes in the carotid plaque status during a 5-year follow-up. J Atheroscler Thromb. 2014; 21: 161-168
8) O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22
9) Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 478-487

10) Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432-1437

11) Iwamoto Y, Maruhashi T, Fujii Y, Idei N, Fujimura N, Mikami S, Kajikawa M, Matsumoto T, Kihara Y, Chayama K, Noma K, Nakashima A, Higashi Y. Intima-media thickness of brachial artery, vascular function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2012; 32: 2295-2303

12) Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126

13) Higashi Y, Noma K, Yoshizumi M, Kihara Y. Oxidative stress and endothelial function in cardiovascular diseases (Review). Circ J 2009; 73: 411-418

14) Celermajer DS, Sorensen KE, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115

15) Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF Jr, Lehan BT, Fan S, Ospyuk E, Vita JA. Clinical correlates and heritability of flow-mediated dilation in the community: The Framingham Heart Study. Circulation 2004; 109: 613-619

16) Soga J, Hata T, Hidaka T, Fujii Y, Idei N, Fujimura N, Mikami S, Maruzuki T, Kihara Y, Chayama K, Kato H, Noma K, Liao JK, Higashi Y, for ROCK investigator group. Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2011; 31: 2353-2359

17) Fujimura N, Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Mikami S, Maruzuki T, Iwamoto Y, Kihara Y, Chayama K, Kato H, Noma K, Liao JK, Higashi Y, for ROCK investigator group. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther 2012; 91: 289-297

18) Maruhashi T, Soga J, Idei N, Fujimura N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Higashi Y. Nitroglycerine-induced Vasodilation for Assessment of Vascular Function: A Comparison with Flow-mediated Vasodilation. Arterioscler Thromb Vasc Biol. 2013; 33: 1401-1408

19) Maruhashi T, Soga J, Idei N, Fujimura N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Higashi Y. Nitroglycerine-induced Vasodilation for Assessment of Vascular Function: A Comparison with Flow-mediated Vasodilation. Arterioscler Thromb Vasc Biol. 2013; 33: 1401-1408

20) Maruhashi T, Soga J, Idei N, Fujimura N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Tomiyama T, Takase B, Yamashina A, Higashi Y. Hyperbilirubinemia, augmentation of endothelial function and decrease in oxidative stress in Gilbert syndrome. Circulation. 2012; 126: 596-603

21) Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40: 505-510

22) Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: A prospective study. Circulation 2002; 105: 1567-1572

23) Brevetti G, Silvestro A, Schiano V, Chiarie M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: Additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 2939-2949

24) Lerman A, Zelis AM. Endothelial function: Cardiac events. Circulation 2005; 111: 363-368

25) Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR, Herrington DM. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: The multiethnic study of atherosclerosis. Circulation 2009; 120: 502-509

26) Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, Celermajer DS. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilatation in adults at risk of atherosclerosis. J Am Coll Cardiol. 1998; 32: 123-127

27) Jarvisalo MJ, Lehtimaki T, Raitakari TO. Determinants of arterial nitrate-mediated dilatation in children: role of oxidized low-density lipoprotein, endothelial function, and carotid intima-media thickness. Circulation. 2004; 109: 2885-2889

28) Maruhashi T, Soga J, Idei N, Fujimura N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Higashi Y. Nitroglycerine-induced Vasodilation for Assessment of Vascular Function: A Comparison with Flow-mediated Vasodilation. Arterioscler Thromb Vasc Biol. 2013; 33: 1401-1408

29) Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Ronnemaa T, Raitakari OT. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation 2004; 110: 2918-2923

30) Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol 2005; 45: 1980-1986

31) Yeboah J, Burke GL, Crouse JR, Herrington DM. Relationship between brachial flow-mediated dilation and carotid intima-media thickness in an elderly cohort: the Cardiovascular Health Study. Atherosclerosis 2008; 197: 840-845

32) Shionoya S. Diagnostic criteria of Buerger’s disease. Int J Cardiol 1998; 66 (Suppl 1): S243-245

33) Chobanian AV, Bakris GL, Black HR, Cushman WC, Green Jr LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572

34) American Diabetes Association: clinical practice recommendations 1999. Diabetes Care 1999; 22 (Suppl. 1): S1-114

35) Executive Summary of The Third Report of The National...
36) Szuba A, Cooke JP. Thromboangiitis obliterans. An update on Buerger’s disease. West J Med. 1998; 168: 255-260
37) Cooper LT, Tse TS, Mikhail MA, McBane RD, Stanson AW, Ballman KV. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger’s disease). J Am Coll Cardiol. 2004; 44: 2410-2411
38) Idei N, Nishioka K, Soga J, Hidaka T, Hata T, Fujii Y, Fujimura N, Maruhashi T, Mikami S, Teragawa H, Kihara Y, Noma K, Chayama K, Higashi Y. Vascular function and circulating progenitor cells in thromboangiitis obliterans (Buerger’s disease) and atherosclerosis obliterans. Hypertension 2011; 57: 70-78